Skip to main content
AbbVie reports positive results from Phase III RA study

AbbVie's oral upadacitinib, or ABT-494, met the primary endpoint of a late-stage trial for patients with moderate to severe rheumatoid arthritis, achieving 20% improvement of a significantly higher portion of patients receiving once-daily 15- and 30-mg doses of the drug at week 12 compared with placebo. The drug also met the secondary endpoint of the study, in which a significantly greater proportion of patients who received both doses of upadacitinib experienced low disease activity at week 12 versus placebo use.

Full Story: